August 6, 2014

Community pharmacists can dramatically help their patients stick to their prescription regimens, according to a new study led by researchers at the University of Pittsburgh School of Pharmacy.

July 14, 2014

Mylan will acquire Abbott's non-U.S. developed markets specialty and branded generics business.

June 13, 2014

GNC Holdings on Friday announced Michael Nuzzo, EVP and CFO, has tendered his resignation in order to accept an executive position at an unnamed private equity-funded consumer products company.

June 11, 2014

Mylan on Wednesday announced the launch of risedronate sodium tablets USP, 150 mg. The drug is the generic version of Actonel tablets from Warner Chilcott and is used for the treatment of osteoporosis in post-menopausal women, according to the company.

June 9, 2014

Mylan on Monday announced the launch of carboplatin injection, 50-mg/5-ml, in multi-dose vials. The drug is the generic version of Paraplatin injection from Bristol-Myers Squibb.

June 5, 2014

McKesson Pharmacy Systems and Automation has launched a pilot program to test its Adherence Performance reporting solution and provide pharmacies with an adherence rating similar to the CMS Star Ratings provided to health plans.

June 2, 2014

Mylan announced on Monday that it has entered into a settlement and license agreement with Pfizer relating to Mylan's abbreviated new drug application filed with the U.S. Food and Drug Administration for celecoxib capsules in 50-mg, 100-mg, 200-mg and 400-mg strengths.

May 29, 2014

Mylan on Thursday announced that it has launched atovaquone and proguanil hydrochloride tablets, 62.5 mg/25 mg and 250 mg/100 mg, the generic version of GlaxoSmithKline's Malarone tablets.

May 27, 2014

Giant Eagle on Tuesday announced the opening of the company’s second Giant Eagle Express, a new 14,000 sq.-ft. neighborhood grocery store format.

May 14, 2014

Mylan on Wednesday announced that it has launched olanzapine orally disintegrating tablets in 5-mg, 10-mg, 15-mg and 20-mg strengths. The drug is the generic version of Zyprexa Zydis tablets from Eli Lilly and Co.

May 6, 2014

ylan last week announced financial results for the three months ended March 31, 2014. The company reported adjusted diluted earnings per share of $0.66, compared to $0.62 for the same period last year, representing a 6% increase.

April 28, 2014

Mylan last week announced that it filed suit against the Food and Drug Administration, challenging the agency's decision regarding generic drug marketing exclusivity on celecoxib capsules, the generic equivalent of Pfizer's Celebrex.

April 25, 2014

GNC Holdings is launching a new national brand campaign: "Beat Average." The campaign is designed to open a conversation with health-and-wellness consumers about their daily personal wellness goals and how GNC can be their ongoing partner and ally in beating average.

April 21, 2014

Mylan on Friday announced that Supreme Court Chief Justice John Roberts has denied Teva's application for an injunction seeking to prevent Mylan's launch of a generic version of Copaxone (glatiramer acetate injection) pending the Supreme Court's decision on Teva's appeal.

April 11, 2014

Mylan on Friday confirmed that a federal district court has granted its request to enforce a settlement agreement between Endo Pharmaceuticals and Mylan settling patent litigation in connection with Mylan's filing of an abbreviated new drug application with the Food and Drug Administration for frovatriptan succinate tablets, 2.5 mg.

March 27, 2014

PANTHERx Specialty Pharmacy on Thursday announced that it has been awarded the exclusive contract to serve as the specialty pharmacy provider for the South Carolina AIDS Drug Assistance Program Direct Dispensing service tier, effective June 1, 2014.

March 25, 2014

Mylan on Monday announced the U.S. District Court for the Northern District of West Virginia ruled in favor of upholding the validity of patents protecting Perforomist (formoterol fumarate) Inhalation Solution.

March 19, 2014

GNC Holdings on Wednesday announced the introduction of a new line of supplement superchargers called the GNC Accelerator Series.

February 3, 2014

Mylan on Monday announced that its subsidiary has launched the world's first trastuzumab biosimilar in India, which will be marketed by Mylan as Hertraz.

January 31, 2014

Mylan announced that its India-based subsidiary, Mylan Pharmaceuticals Private Limited, has been named Gilead Sciences' branded medicines business partner for India.

January 28, 2014

Women who are deficient in vitamin D in the first 26 weeks of their pregnancy may be at risk of developing severe preeclampsia, a potentially life-threatening disorder diagnosed by an increase in blood pressure and protein in the urine, according to research by the University of Pittsburgh Graduate School of Public Health.

January 24, 2014

Giant Eagle is making a push into Indiana with a Market District concept and GetGo, a convenience store, planned just outside of Indianapolis, according to published reports.

January 23, 2014

Mylan announced that its U.S.-based subsidiary has launched repaglinide tablets, a generic version of Novo Nordisk's Prandin.

January 9, 2014

Mylan has launched a generic drug for preventing rejection of transplanted organs, the company said Thursday.